Blueprint Medicines' (BPMC) Ayvakit Aids Growth Amid Rivalry

Blueprint Medicines' (BPMC) Ayvakit, which has been approved to treat PDGFRA Exon 18 mutant gastrointestinal stromal tumors, has seen strong uptake since approval. However, stiff competition remains a headwind.

from Entrepreneur https://ift.tt/3Dm3PX3
https://ift.tt/31qgefd